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c2(20) = 96.73, CFI = 0.90, GFI = 0.94, RMSEA = 0.10. The
results indicated that the “felt down, depressed or hopeless”
item was the most reliable indicator of the PHQ. CONCLU-
SION: Results provided the evidence of the reliability and
validity of the PHQ. The measure may be useful for screening,
developing and tailoring interventions to the diabetic individu-
als’ level of depression.
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OBJECTIVE: To assess the burden of uncontrolled asthma (UA)
on HRQOL of the child and their family. METHODS: An
internet-based survey was administered to caregivers of children
aged 6–12 years with moderate to severe asthma (severity
and control based on NAEPP guidelines). The caregiver question-
naire assessed pediatric asthma symptoms, rescue medication
use, activity limitation, and included the Child Health
Questionnaire—Parent Form 28 (CHQ-PF28), a generic instru-
ment measuring HRQOL in children and their family. Mean
CHQ-PF28 scores were calculated (ranging from 0–100, with
lower scores representing greater impairment) and compared
between UA and controlled asthma (CA) groups using the two-
sample t-test. RESULTS: A total of 4,514 of 16,396 invited to
participate responded. A total of 473 satisﬁed study inclusion
criteria; 360 were caregivers of children with UA and 113 for
children with CA. Seven out of 8 child-related CHQ-PF28 scale
scores were signiﬁcantly lower among children with UA versus
CA with the greatest differences in physical functioning
(mean difference = 26.8, P < 0.0001) and physical role limita-
tions (mean difference = 20.0, P < 0.0001). Physical (mean
difference = 11.7, P < 0.0001) and psychosocial (mean differ-
ence = 5.6, P < 0.0001) summary scales were both signiﬁcantly
lower among children with UA. Caregivers of children with UA
had signiﬁcantly lower scores on both parent-related scales of
emotional (mean difference = 20.8, P < 0.0001) and time (mean
difference = 16.3, P < 0.0001) impact, and 1 of 2 family-related
scales (activities, mean difference = 19.3, P < 0.0001). CON-
CLUSION: Uncontrolled asthma was associated with signiﬁcant
impairment in HRQOL, extending beyond the physical health of
the child to their psychosocial development. Additionally, uncon-
trolled pediatric asthma had a signiﬁcant HRQOL impact on the
caregiver and family.
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OBJECTIVE: Relapsed small cell lung cancer (SCLC) carries a
poor prognosis and is associated with poor health-related
quality of life (HRQoL). This study assesses the impact of oral
topotecan (OT) on HRQoL when used as second-line treatment
for relapsed SCLC. METHODS: Data from a randomized,
open-label, multicenter clinical trial were analyzed, including
141 patients with relapsed SCLC receiving either OT plus best
supportive care (BSC) or BSC alone. EQ-5D, a widely used
measure of HRQoL that produces both a visual analogue scale
(VAS) and an index-based utility score, was administered at
baseline and subsequently at three-week intervals. Changes in
HRQoL from baseline were compared between two groups by
measuring 1) changes between baseline and last evaluation, and
2) changes between baseline and all on-treatment evaluations
(pooled analysis). Published criteria for interpretation of mini-
mally important differences (MID) in cancer, i.e., UK-based
utility score changes of 0.10 or more and VAS score changes of
8 or more, were used to further interpret results (Pickard AS,
et al. HQLO, 2007). RESULTS: Patients receiving OT + BSC
experienced better HRQoL outcomes compared to patients
receiving BSC alone. Mean declines from baseline to the last
evaluation were signiﬁcantly smaller in the OT + BSC than BSC
alone group in EQ-5D utility (-0.10 vs. -0.30, p = 0.0078) and
VAS (-3.98 vs. -14.46, p = 0.0044) scores. Similarly, in the
pooled analysis, the OT + BSC group exhibited signiﬁcantly
smaller declines from baseline than the BSC alone group in both
EQ-5D utility (-0.04 vs. -0.18, p = 0.0045) and VAS (-0.71 vs.
-8.83, p = 0.0035) scores. Using previously established criteria
for MIDs, the differences in HRQoL decline between two groups
were statistically signiﬁcant and clinically meaningful. CON-
CLUSION: Patients receiving OT + BSC experienced smaller
declines in HRQoL from baseline than patients receiving BSC
alone. Differences in change from baseline between groups
exceeded MIDs from previous studies, indicating a meaningful
clinical beneﬁt.
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OBJECTIVE: To estimate the burden of exposure to medications
associated with known or suspected risk of fetal harm among
pregnant women in Regione Emilia-Romagna (RER), Italy.
METHODS: A prevalence study was conducted using the RER
health care database, including data for the entire RER popu-
lation of about 4 million inhabitants. Female residents of RER
who delivered a baby in a hospital between January 1, 2004
and December 31, 2004 were identiﬁed via ICD-9-CM codes.
All prescription drug data were reviewed for the 270 days
leading up to date of delivery. Drugs were grouped into preg-
nancy risk categories (A, B, C, D, X) using established classi-
ﬁcation systems. Contraindicated drugs were deﬁned as
category X drugs and potentially dangerous drugs were deﬁned
as category D drugs. Women exposed to contraindicated and
potentially dangerous drugs in the 270 days prior to delivery
were identiﬁed. RESULTS: Among the 33,343 deliveries iden-
tiﬁed in 2004, 70% were exposed to at least one prescription
medication in the 270 days prior to delivery. Approximately
1% of women were exposed to drugs contraindicated in preg-
nancy (category X), including 189 women (0.6%) receiving
these drugs during the ﬁrst trimester. Approximately 1.5% of
women were exposed to potentially dangerous (category D)
drugs. Measurable proportions of women were exposed to
ACE-inhibitors (0.79%) and HMG-CoA reductase inhibitors
(0.28%), which have recently been linked to risk of fetal mal-
formations. CONCLUSIONS: For the entire RER population,
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